Dr. Alan Kozikowski on How He Designs New Psilocybin Drug to Treat Depression
Автор: Bright Minds Biosciences
Загружено: 2020-06-05
Просмотров: 1198
Dr. Alan Kozikowski (co-founder at Bright Minds Biosciences; Actuate Therapeutics) at the Future of Psychedelics Summit 2020 (May 2).
Alan talks about his previous work as a drug designer: he discusses Phencyclidine ("Angel Dust") and "Nocaine". Currently, Alan is involved at Bright Minds Biosciences - developing the next generation of psychedelics for treating mental health disorders and cluster headaches.
The scientific team at Bright Minds Biosciences is working on the development of novel compounds of psilocybin (an active compound found in magic mushroom), which will have fewer side effects, but strong therapeutic action. New compounds will cause no interaction with 5-HT2B receptors (which causes cardiac diseases), while still retain the activity in 5-HT2A and 5-HT2C receptors. Some of the compounds already gone through animal studying, which proved their safety.
Watch all sessions from the Future of Psychedelics Summit 2020 http://futureofpsychedelics.com
Learn more about Bright Minds Biosciences: https://brightmindsbio.com
Follow Bright Minds Biosciences on Twitter: / brightmindsbio
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
